申请人:Pfizer Inc.
公开号:US04420426A1
公开(公告)日:1983-12-13
A process for the preparation of penicillanic acid 1,1-dioxide and esters thereof readily hydrolyzable in vivo, which comprises oxidation of a 6-halopenicillanic acid, or an ester thereof readily hydrolyzable in vivo, to the corresponding 6-halopenicillanic acid 1,1-dioxide or ester thereof, followed by dehalogenation (e.g. by hydrogenolysis). Certain of the 6-halopenicillanic acid 1,1-dioxides and esters thereof readily hydrolyzable in vivo are novel intermediates. Penicillanic acid 1,1-dioxide, and esters thereof readily hydrolyzable in vivo are known compounds which are beta-lactamase inhibitors and which enhance the effectiveness of certain beta-lactam antibiotics (e.g. the penicillins) in the treatment of bacterial infections in mammals, particularly humans.
一种制备在体内容易水解的青霉烷酸1,1-二氧化物及其酯的方法,包括将6-卤代青霉酸或在体内容易水解的其酯氧化为相应的6-卤代青霉酸1,1-二氧化物或其酯,然后进行去卤代反应(例如氢解)。其中一些在体内容易水解的6-卤代青霉酸1,1-二氧化物及其酯是新颖的中间体。青霉烷酸1,1-二氧化物及其在体内容易水解的酯是已知的化合物,它们是β-内酰胺酶抑制剂,可以增强特定β-内酰胺类抗生素(例如青霉素)在哺乳动物,尤其是人类的细菌感染治疗中的有效性。